ProKidney (NASDAQ:PROK – Get Free Report) and Biomerica (NASDAQ:BMRA – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, valuation, analyst recommendations and institutional ownership.
Institutional and Insider Ownership
51.6% of ProKidney shares are owned by institutional investors. Comparatively, 22.3% of Biomerica shares are owned by institutional investors. 41.5% of ProKidney shares are owned by company insiders. Comparatively, 18.0% of Biomerica shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Volatility & Risk
ProKidney has a beta of 1.79, meaning that its stock price is 79% more volatile than the S&P 500. Comparatively, Biomerica has a beta of 0.06, meaning that its stock price is 94% less volatile than the S&P 500.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ProKidney | 2 | 1 | 3 | 0 | 2.17 |
| Biomerica | 1 | 0 | 0 | 0 | 1.00 |
ProKidney presently has a consensus price target of $6.25, indicating a potential upside of 165.96%. Given ProKidney’s stronger consensus rating and higher possible upside, analysts clearly believe ProKidney is more favorable than Biomerica.
Profitability
This table compares ProKidney and Biomerica’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ProKidney | -9,547.45% | N/A | -18.09% |
| Biomerica | -74.84% | -73.44% | -53.26% |
Valuation & Earnings
This table compares ProKidney and Biomerica”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ProKidney | $80,000.00 | 8,836.88 | -$61.19 million | ($0.55) | -4.27 |
| Biomerica | $5.31 million | 1.38 | -$4.97 million | ($0.96) | -2.58 |
Biomerica has higher revenue and earnings than ProKidney. ProKidney is trading at a lower price-to-earnings ratio than Biomerica, indicating that it is currently the more affordable of the two stocks.
Summary
ProKidney beats Biomerica on 10 of the 14 factors compared between the two stocks.
About ProKidney
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.
About Biomerica
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
Receive News & Ratings for ProKidney Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProKidney and related companies with MarketBeat.com's FREE daily email newsletter.
